#China #biopharmaceuticals #Hangzhou #Innovent Biologics #Altruist Biologics

Altruist Biologics Completes First Commercial PPQ Campaign

In a groundbreaking achievement for the biopharmaceutical industry, Altruist Biologics has successfully completed its first commercial Process Performance Qualification (PPQ) campaign at its state-of-the-art facility in Hangzhou, China. This development not only underscores the company’s commitment to excellence but also sets a new benchmark in large-scale manufacturing of biopharmaceuticals.

Altruist Biologics, a subsidiary of Innovent Biologics, reported that the campaign involved the successful execution of three consecutive batches, each utilizing their advanced 20,000-liter stainless steel bioreactors. This significant milestone demonstrates the company's capability to operate at a large scale while maintaining stringent production quality. The successful validation of these production processes highlights Altruist's innovative technology and robust quality management systems, aligned with its dedication to providing reliable and scalable manufacturing solutions to its clients.

Cost Efficiency and Yield Improvement

One of the standout achievements of the PPQ campaign was the substantial reduction in manufacturing costs—bringing them down to less than $50 per gram of monoclonal antibody drug substance. This impressive cost-efficiency was achieved through economies of scale and the implementation of advanced automation strategies. Moreover, Altruist Biologics reported an increase in yield by up to 80%, a testament to their focused effort on continuous process optimization and intensification.

Dr. Kaisong Zhou, the Chairman and CEO of Altruist Biologics, emphasized the importance of this accomplishment, stating, _“The completion of our first commercial PPQ campaign marks a pivotal moment in our evolution as a global manufacturing partner. The ability to successfully execute three consecutive batches at this scale reflects our operational maturity and the strength of our quality systems.”_ These remarks point towards the significant strides made by the company not just in production capability, but also in maintaining high standards of quality throughout the process.

A Vision for Expansion

Looking ahead, the Hangzhou facility is set for even further expansion, with plans to add four additional 20,000-liter stainless steel bioreactors and six 2,000-liter single-use bioreactors by 2027. This expansion will nearly double the site's production capacity from 80,000 liters to an impressive 172,000 liters, positioning Altruist as a leader in the biopharmaceutical manufacturing sector.

The Hangzhou site is already recognized as the largest of its kind in China, featuring four operational 20,000-liter stainless steel bioreactors. The introduction of additional bioreactors will enhance the site’s capability to support the increasing global demand for high-quality biopharmaceuticals. This ambitious expansion plan reflects Altruist’s proactive approach to meeting future market needs while upholding its commitment to operational excellence and innovation.

Commitment to Quality and Innovation

Altruist Biologics operates with a focus on delivering high-quality biopharmaceuticals and has successfully supported the commercialization of numerous drugs, boasting a remarkable track record of over 2,000 commercial batches with a success rate of greater than 99.8%. With state-of-the-art cGMP facilities across China, including their locations in Suzhou and Hangzhou, Altruist is well-equipped to tackle the challenges of drug development and manufacturing.

In a world where the demand for effective therapies continues to grow, Altruist Biologics remains steadfast in its mission to provide high-quality, affordable biopharmaceutical solutions. The company’s recent achievements not only showcase its operational prowess but also highlight its dedication to improving the health outcomes of patients globally.

For further insights into Altruist Biologics and their end-to-end service capabilities, visit www.altruistbio.com.

Altruist Biologics is poised for continued success and remains committed to innovating within the biopharmaceutical landscape, ensuring that it meets and exceeds the expectations of its clients as they navigate their path from development to commercial supply.